All types of healthcare, including measurable residual disease (MRD) testing should be available to everyone throughout Europe. Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, explains how groups such as EuroMRD Consortium are making this possible.
European-wide MRD screening should be available for all
